SELLAS Life Sciences Group, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
SELLAS Life Sciences Group, Inc. (SLS) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $3.17 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-22.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2019-03-22
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2017 was $3.17M, a 795.20% increase from fiscal 2016.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2016 was $354.00K.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2014 was $134.00K, a 79.19% decline from fiscal 2013.
- SELLAS Life Sciences Group, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2013 was $644.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|
| 2017-12-31 | $3.17M 10-K · filed 2019-03-22 |
| 2016-12-31 | $354.00K 10-K · filed 2018-04-13 |
| 2014-12-31 | $134.00K 10-K · filed 2017-03-15 |
| 2013-12-31 | $644.00K 10-K/A · filed 2016-04-15 |
| 2012-12-31 | $600.00K 8-K · filed 2015-12-04 |
| 2011-12-31 | -$15.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |